New Peer-Reviewed Paper in Expert Opinionon Investigational Drugs Features Nymox NX-1207 Drug for BPH -- ArticleSuggests Nymox Drug Has Potential to Significantly Impact CurrentPattern of Treatment for BPH1/7/2010 10:30:26 AM - GlobeNewswire
HASBROUCK HEIGHTS, N.J., Jan 7, 2010 (GlobeNewswire via COMTEX News Network) --
NymoxPharmaceutical Corporation (Nasdaq:NYMX) announced today thepublication of a new peer-reviewed paper in Expert Opinion onInvestigational Drugs featuring NX-1207, the Company's innovativetreatment for benign prostatic hyperplasia (BPH). NX-1207 is currentlyin Phase III trials. The paper, "NX-1207: a novel investigational drugfor the treatment of benign prostatic hyperplasia," is written by NealShore MD FACS, Medical Director of the Carolina Urologic ResearchCenter, Myrtle Beach, SC. Dr. Shore is a well known expert in urologyand has participated as a clinical investigator in five of the NX-1207clinical trials as well as seven follow-up studies of the drug. Thepaper is available online athttps://informahealthcare.com/doi/abs/10.1517/13543780903555196.
InExpert Opinion, the author writes, "Regarding existing oral drugtherapies, the use of NX-1207 would obviate daily and lifelongcompliance issues as well as the ongoing concerns of polypharmacyfacing the elderly and the attendant risk for drug-drug interactions.In comparison to office-based MIST options, the transrectal injectionapproach afforded by NX-1207, both anesthetic/analgesic free as well ascatheter free, will be quite compelling to most patients. If theongoing Phase III trials can duplicate the success seen in earliertrials, for both efficacy and safety, then the administration ofNX-1207 should be expected to significantly impact the current patternof treatment options employed by urologists for their patients withBPH."
NX-1207 is a novel patented drug developed by Nymox whichis currently in Phase 3 trials. The drug has successfully completed aseries of blinded controlled multi-center U.S. clinical trials where asingle dose of NX-1207 has been found to produce symptomaticimprovements about double that reported for currently approved BPHdrugs without causing the sexual or cardiovascular side effectsassociated with those drugs. Follow-up studies have shown evidence oflong lasting benefit with a significant proportion of men who receiveda single dose reporting maintained improvement in BPH symptoms for upto 5 years.
NX-1207 is a new targeted approach to the treatmentof BPH. The drug is administered by a urologist in an office settingdirectly into the zone of the prostate where the enlargement occurs.The procedure takes only a few minutes, causes little or no pain ordiscomfort, and does not require anaesthesia or catheterization.Urologists in the U.S. have expressed very positive comments aboutNX-1207's potential to improve the care of millions of men with BPH.
BPHtreatment represents a growing market with more than 100 million menworldwide being estimated to suffer from BPH symptoms. The disorder isa common affliction of older men, affecting approximately half of menover age 50 and close to 90% of men by age 80, and is associated withgrowth in prostate size as men age.